nejm retatrutide 2023年度回顧】 Notable Articles of 2023 Day 3: Triple–Hormone-Receptor Agonist for Obesity — A Phase 2 Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Retatrutide Dosing Guide for Researchers
Description
52% women) met the studys inclusion criteria and were matched for potential confounders using propensity score matching (n = 15,908 per group)
Masaki H, Shimamoto K, Inokuchi S, Ishizaki S
doi: 10.3390/molecules26216549
Food & Function , 8(8), 2653-2671
Rapid weight loss from GLP-1 medications is linked to reduced bone density, especially in women over 50 after menopause
No changes were made to other antidiabetic medications or lifestyle interventions during the observation period
